Ongoing Study:
Phase 1a Study in COVID-19 in the United Kingdom
First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Overlapping Single and Multiple Ascending Dose Escalation Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers
Study Highlights:
Enrolling: ~80 Subjects
Treatment period: Single ascending dose (SAD) and multiple ascending dosing (MAD)
Primary Endpoint: Safety and tolerability
For complete study details, please view the study listing on clinicaltrials.gov: ClinicalTrials.gov Identifier: NCT05195723